-0.110 (-1.95%)
Range 5.450 - 5.680   (4.22%)
Open 5.570
Previous Close 5.650
Buy Price 5.510
Buy Volume 8
Sell Price 5.520
Sell Volume 13
Volume 512,864
Value -
Measurement Type Value
EPS (USD) -2.032
Trailing EPS (USD) -1.153
NAV (USD) 1.14
Cash In Hand (USD) 2.34
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 5.149
Price / Cash In Hand 2.508
Issued & Paid-up Shares 76,610,100
Treasury Shares -
Market Cap (M) 449.701
Par Value (USD) n.a.
Beta - 75 Days 1.435
R-Squared - 75 Days(%) 9.26
Beta - 500 Days 1.245
R-Squared - 500 Days(%) 17.65
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 22 Jan 2022 03:52.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 10 Mar 2022
View All Events


Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company�s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company�s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company�s product candidates are OTX-DP and OTX-TP. OTX-DP is in Phase III clinical development for post-surgical ocular inflammation and pain. OTX-TP is in Phase II clinical development for glaucoma and ocular hypertension. These product candidates combine its hydrogel technology with the United States Food and Drug Administration (FDA), approved therapeutic agents with the goal of providing sustained delivery of drug to the eye.

There are 2 followers